Compassionate Use of Investigational New Drugs: Is the Current Process Effective? : Hearing Before the Committee on Government Reform, House of Representatives, One Hundred Seventh Congress, First Session, June 20, 2001
U.S. Government Printing Office, 2002 - Antineoplastic agents - 150 pages
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
Abigail access to experimental ANN DAVIS approval process Astrazeneca Barr Baxter beneﬁt biologic breast cancer Burroughs BURTON cancer patients Chairman chemo chemotherapy clinical trials colon cancer colorectal cancer Committee compassionate use program Dan Burton David David’s doctor DAVIS OF VIRGINIA deﬁned DELANEY difﬁcult disease drug available drug companies drug development early access programs effect efﬁcacy experimental drugs experimental treatments facility FDA approval FDA’s ﬁnd ﬁrst give going Government Reform head and neck hearing hope hospice ImClone Systems important investigational drugs IRESSA issue JO ANN DAVIS Kellum live manufacturing months MORELLA neck cancer needs oncologist oncology phase physicians prognosis protocol questions requests safety Samuel Waksal Santino signiﬁcant speciﬁc sponsor surgery survival talking tell TEMPLE terminally ill testimony Thank things tients treated treatment IND treatment options tumor WAKSAL WELDON wife